Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study of ceftriaxone and amoxicillin treatment in patients with acute coronary syndrome, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on treating patients with acute coronary syndrome, which includes conditions such as ST-elevation myocardial infarction (heart attack with specific changes in heart electrical activity), non-ST-elevation myocardial infarction (another type of heart attack), and coronary artery disease (narrowing of heart blood vessels). The purpose is to determine if antibiotic treatment can reduce complications in patients with these heart conditions.

The study will use two different antibiotics: ceftriaxone, which is given through an intravenous infusion (through a vein), and amoxicillin, which is taken as tablets by mouth. These medications will target specific bacteria that have been found in the fatty deposits that build up in the arteries of patients with heart attacks.

During the study, patients will receive antibiotic treatment for up to two weeks. The medications will be used to target bacteria that are commonly found in complicated artery blockages. Patients will be monitored for heart-related events and complications over several years after receiving the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    After being diagnosed with heart attack (myocardial infarction) and agreeing to participate, you will receive treatment in two forms:

    - Intravenous infusion of ceftriaxone (2g solution)

    - Oral tablets of amoxicillin (500mg film-coated tablets)

    This treatment targets bacteria that may be involved in heart vessel blockages

  2. Step 2

    Heart examination procedure

    You will undergo an angiography - a procedure to examine your heart blood vessels

    This examination is part of standard care for your condition

  3. Step 3

    3-month follow-up

    Your health status will be evaluated after 3 months

    The medical team will check for any heart or brain-related events that may have occurred

  4. Step 4

    12-month follow-up

    A comprehensive health assessment will be conducted after one year

    This evaluation will check for any:
    - Heart-related deaths
    - New heart attacks
    - Hospital stays due to severe heart failure
    - Stroke or mini-stroke episodes

  5. Step 5

    Long-term follow-up

    Additional health assessments will be performed at 2 years and 5 years after treatment

    These evaluations will monitor your long-term heart and brain health

Who can join the trial?

12 criteria

  • Patient must be 18 years of age or older
  • Patient must have been diagnosed with either:
    • STEMI (heart attack where a major heart artery is completely blocked)
    • NSTEMI (heart attack where a heart artery is partially blocked)
    • Patient must be scheduled for angiography (a procedure to examine blood vessels of the heart)
    • Patient must have at least 3 of the following risk factors:
      • High blood pressure (hypertension)
      • Diabetes
      • Moderate kidney problems (kidney filtration rate below 60ml/min)
      • Peripheral arterial disease (narrowing of arteries outside the heart)
      • Multiple blocked heart arteries
      • Previous heart attack
      • Previous stroke or mini-stroke (TIA)
      • Patient must be able to provide informed consent (agree to participate after understanding study details)

Who cannot join the trial?

14 criteria

  • History of allergic reaction to antibiotics that will be used in the study
  • Current or recent (within 2 weeks) use of antibiotics
  • Severe kidney problems (as this may affect how the body processes the medication)
  • Severe liver disease that could interfere with medication metabolism
  • Pregnancy or breastfeeding
  • Participation in another clinical trial within the past 30 days
  • Life expectancy less than 12 months due to other medical conditions
  • Unable to provide informed consent (written permission to participate in the study)
  • History of severe gastrointestinal problems that could affect medication absorption
  • Active bacterial infection requiring immediate antibiotic treatment
  • Known blood disorders that could affect study results
  • Immunodeficiency conditions (weakened immune system)
  • History of organ transplantation
  • Severe mental illness that could affect ability to follow study procedures
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Based on the provided trial information about antibiotic treatment in acute coronary syndrome, I cannot specifically identify the exact medications used, as they are not explicitly mentioned in the source data. The trial appears to involve antibiotics targeting bacteria found in atherosclerotic plaques, but the specific antibiotic names are not provided in the source material. Without more detailed information about the specific medications used in this trial, I cannot provide accurate descriptions of the treatments involved. To maintain accuracy and avoid speculation, I would need additional data about which particular antibiotics or other medications were used in this clinical trial.

What is already known about the treatment

  • Azithromycin

    An oral antibiotic medication commonly used in clinical trials for cardiovascular conditions, particularly in cases of acute coronary syndrome. This macrolide antibiotic works by inhibiting bacterial protein synthesis and has shown potential anti-inflammatory properties that may help reduce atherosclerotic plaque formation in coronary arteries. Administered as oral tablets or capsules, it is being investigated for its possible role in preventing major adverse cardiac and cerebrovascular events (MACCE) in patients with acute myocardial infarction by targeting specific bacteria found in complex atherosclerotic plaques.

  • Roxithromycin

    A macrolide antibiotic medication administered orally that has been studied in cardiovascular clinical trials, particularly in relation to coronary artery disease and acute coronary syndromes. The medication works by stopping bacterial growth through inhibition of protein synthesis and demonstrates anti-inflammatory properties that may affect atherosclerotic plaque stability. It is being evaluated for its potential to reduce cardiac events in patients with myocardial infarction by targeting specific bacteria associated with atherosclerotic plaques.

Investigated diseases

  • Non-ST-elevation myocardial infarction (NSTEMI)

    A type of heart attack where the coronary artery is partially blocked, reducing blood flow to part of the heart muscle. The blockage typically occurs due to a buildup of fatty deposits, cholesterol, and other substances that form plaque in the arteries. The condition develops when this plaque ruptures, causing blood clots to form and restrict blood flow.

  • ST-elevation myocardial infarction (STEMI)

    A severe type of heart attack where one of the heart's major arteries is completely blocked, preventing blood from reaching a large area of the heart. This blockage leads to the death of heart muscle tissue in the affected area. The condition typically causes intense chest pain and other symptoms that develop suddenly.

  • Coronary artery disease

    A condition where the major blood vessels that supply the heart become damaged or diseased. It typically develops over many years as fatty deposits build up inside the coronary arteries, causing them to narrow and become less flexible. This process, known as atherosclerosis, reduces blood flow to the heart muscle and can lead to chest pain and other symptoms.

  • Heart failure

    A chronic condition where the heart cannot pump blood effectively enough to meet the body's needs. The heart continues to work but becomes weaker over time or too stiff to fill properly. This leads to fluid buildup in the lungs and other body tissues, causing symptoms like shortness of breath and fatigue.

  • Stroke

    A condition that occurs when blood flow to part of the brain is interrupted, either by a blockage or a burst blood vessel. This disruption of blood flow prevents brain tissue from getting oxygen and nutrients. Brain cells begin to die within minutes of oxygen deprivation, leading to various symptoms depending on which area of the brain is affected.

  • Transient Ischemic Attack (TIA)

    A temporary interruption of blood flow to part of the brain, causing brief stroke-like symptoms. Unlike a stroke, a TIA typically resolves within minutes to hours. The blood flow disruption is temporary and does not cause permanent brain damage.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2025-522136-14-00Estimated enrolment1 070 patientsSponsorTAYS Sydaenkeskus Oy

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).